New CEO and President at Boule Diagnostics
The board of directors at Boule Diagnostics has today appointed Torben Nielsen as the new CEO and President, effective no later than June 14, 2024. Torben Nielsen will replace Jesper Söderqvist, who has been the CEO since 2020. Jesper will be available to the company during a transition period and will leave his position at latest by April 15, 2024. If necessary, the company’s CFO, Holger Lembrér, will act as interim CEO until Torben Nielsen assumes his role.
Torben Nielsen most recently held the position as Executive Vice President in the Analytical Solutions and Customer Enablement business area at PerkinElmer. He brings extensive experience from the hematology market, having worked at Radiometer from 2005 to 2019. His roles included General Manager for Radiometer America and previously Sales Manager for Western Europe. Nielsen also has broader experience in the medical technology industry, having served as Sales Manager for EMEA in the subsidiary companies Ormco and Spark within the Envista group.
“The Board would like to thank Jesper Söderqvist for his four years at Boule. Jesper has led Boule through very challenging times, including the effects of geopolitical uncertainty and, most notably, a global pandemic. As Boule enters its next phase, the board believes that a different leadership approach is needed,” says Torben Jörgensen, Chairman of the Board at Boule Diagnostics.
“Torben Nielsen, with his extensive experience in international sales, not only within segments closely related to Boule’s markets but also in other healthcare markets with a similar business model, will make a significant contribution. We are facing a product launch of a new hematology platform, increased focus on the veterinary segment, and expansion of our OEM business,” adds Torben Jörgensen, Chairman of the Board at Boule Diagnostics.
“I am very much looking forward to taking on the role of CEO at Boule Diagnostics, a company with a strong market position, brands associated with robustness and quality, and many loyal customers. Boule benefits from several global trends. With a new product platform and excellent opportunities to further develop and expand the business, I am excited to take the company to the next level,” says Torben Nielsen, the incoming CEO of Boule Diagnostics.
For more information, please contact:
Torben Jörgensen, Chairman of Boule Diagnostics AB, torben.jorgensen@biotage.com
Holger Lembrér, CFO, Boule Diagnostics AB, phone +46 (0)72-230 77 10
About Boule Diagnostics AB (publ)
Boule Diagnostics AB (publ) is a global diagnostics company specializing in near-patient, decentralized blood diagnostics and one of the few companies in the global diagnostics market that conducts its own development, manufacturing and marketing of instruments and consumables for blood diagnostics. The Company primarily serves hospitals, clinics, laboratories and other diagnostics companies to which it offers complete systems for blood diagnostics (hematology) in both the human and veterinary areas. Boule has strong positions in important emerging markets such as in Asia and in recent years has improved its position in the fast-growing veterinary market. Operations are conducted through operating subsidiaries in Sweden, the United States, Mexico and Russia. The Group reported net sales of SEK 571 million in 2023 and has more than 200 employees. Sales are conducted globally, predominantly through the company’s 200 or so distributors in over 100 countries, supported by Boule’s own local sales and service personnel. Boule has been listed on Nasdaq Stockholm since 2011. http://www.boule.com
This information is information that Boule Diagnostics AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 10:45 CET on March 14, 2024.
